Related Experiment Video
Updated: Mar 1, 2026

Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in
F Giesert1, L Glasl2, A Zimprich2
1Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany; Technische Universität München-Weihenstephan, Lehrstuhl für Entwicklungsgenetik, c/o Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.
Abstract:
The aim of the present study was to further explore the in vivo function of the Leucine-rich repeat kinase 2 (LRRK2)-gene, which is mutated in certain familial forms of Parkinson's disease (PD). We generated a mouse model harboring the disease-associated point mutation R1441C in the GTPase domain of the endogenous murine LRRK2 gene (LRRK2 R1441C line) and performed a comprehensive analysis of these animals throughout lifespan in comparison with an existing knockdown line of LRRK2 (LRRK2 knockdown line). Animals of both lines do not exhibit severe motor dysfunction or pathological signs of neurodegeneration neither at young nor old age. However, at old age the homozygous LRRK2 R1441C animals exhibit clear phenotypes related to the prodromal phase of PD such as impairments in fine motor tasks, gait, and olfaction. These phenotypes are only marginally observable in the LRRK2 knockdown animals, possibly due to activation of compensatory mechanisms as suggested by in vitro studies of synaptic transmission. Thus, at the organismal level the LRRK2 R1441C mutation does not emerge as a loss of function of the protein, but induces mutation specific deficits. Furthermore, judged by the phenotypes presented, the LRRK2-R1441C knock-in line is a valid preclinical model for the prodromal phase of PD.
Insights
The Leucine-rich repeat kinase 2 (LRRK2) R1441C mutation in mice models early Parkinson's disease symptoms. This LRRK2 mutation causes specific deficits, not a general loss of function, making it a valuable preclinical model.
Area of Science:
- Neuroscience
- Genetics
- Parkinson's Disease Research
Background:
- Mutations in the Leucine-rich repeat kinase 2 (LRRK2) gene are linked to familial Parkinson's disease (PD).
- Understanding the in vivo function of LRRK2 is crucial for developing effective PD treatments.
Purpose of the Study:
- To investigate the in vivo function of the LRRK2 gene, specifically the R1441C mutation associated with PD.
- To comprehensively analyze a novel LRRK2 R1441C knock-in mouse model throughout its lifespan.
Main Methods:
- Generation of a mouse model with the endogenous LRRK2 R1441C point mutation.
- Lifespan analysis and comparison with an existing LRRK2 knockdown mouse line.
- Assessment of motor function, gait, olfaction, and neurodegeneration signs.
Main Results:
- Neither LRRK2 R1441C nor LRRK2 knockdown mice showed severe motor deficits or neurodegeneration.
- Homozygous LRRK2 R1441C mice exhibited prodromal PD phenotypes (impaired fine motor skills, gait, olfaction) in old age.
- LRRK2 knockdown mice showed only marginal phenotypes, suggesting compensatory mechanisms.
Conclusions:
- The LRRK2 R1441C mutation induces mutation-specific deficits rather than a general loss of function.
- The LRRK2-R1441C knock-in mouse line serves as a valid preclinical model for the prodromal phase of Parkinson's disease.
Related Concept Videos
Lysosomal Hydrolases
Parkinson's Disease: Overview

